“…Considering that the same set of experimental conditions was tested for MSC from the bone marrow, adipose tissue, synovial tissue and UCM, this suggests that intrinsic features of MSCs from different sources should be considered when developing strategies for large‐scale MSC manufacturing. Indeed, others have used stirred microcarrier‐based culture systems for the expansion of UCM MSCs, although using poorly defined xenogeneic components, such as FBS as a culture supplement (Hupfeld et al , ; Teixeira et al , ; Zhao et al , ) or animal‐derived microcarriers (Zhao et al , ) making GMP compliance difficult. In this context, taking into account the high proliferative potential of UCM MSCs cultured in DMEM + 5% UltraGRO TM under static conditions and that cells retained their immunophenotype and multilineage differentiation potential after five consecutive passages, the use of this HPL‐based product was exploited as a culture component to expand these cells in the previously established plastic microcarrier‐based culture system (dos Santos et al , ; Carmelo et al , ).…”